EGFR and neoplasm: CD49b was expressed in 71.11% (32/45) of normal tissues, CD73 in 86.05% (37/43), and EGFR in 46.67% (21/45), which may cause more on-target-off-tumor toxicities in contrast to ICAM1 in 19.15% (9/47).